Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Understanding KRAS Imbalance as a Mediator of Pancreatic Tumour Aggression and Metastasis
FY 2019-20
Summary
"Pancreatic ductal adenocarcinoma (pancreatic cancer) is predicted to become the second leading cause of cancer related deaths within the next several years. Patients often present with highly malignant disease with limited treatment options. This highlights the need to understand the molecular mechanisms driving disease progression to better understand how to treat these patients. One particular gene imbalance that is highly prevalent in pancreatic cancer is in KRAS, a GTPase that is mutated in more than 90% of pancreatic cancer cases. When genome instability occurs, it creates an imbalance that increases the mutant:wildtype ratio of this gene. Recent work from our laboratory has shown that pancreatic cancer with a copy number imbalance in mutant KRAS are more aggressive and chemoresistant compared to cases where KRAS is balanced (equal number of mutated and wild type). I hypothesize that KRAS imbalances lead to upregulation of genes that mediate a survival/growth and contribute to therapy resistance. This project seeks to identify genes and pathways that are affected by mutant KRAS imbalance, to uncover molecular vulnerabilities that can eventually be targeted or combined with current chemotherapy. To do this I will generate a target genes using bulk RNA-seq from our recent paper (Chan et al., Nature Genetics, accepted) and use CRISPR to knockout these genes in a pancreatic cancer-derived 3D culture system (organoids). By understanding why these tumours are resistant to the current standards of care it is hoped that new therapeutic approaches can be discovered to improve patient prognosis. "
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
429076
Name
Woo Tristan
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Understanding KRAS Imbalance as a Mediator of Pancreatic Tumour Aggression and Metastasis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chemoresistance; Copy Number Aberrations; Crispr; Gene Imbalance; Kras; Metastasis; Organoids; Pancreatic Cancer; Rna-Seq; Transcriptomic Signature
Abstract
"Pancreatic ductal adenocarcinoma (pancreatic cancer) is predicted to become the second leading cause of cancer related deaths within the next several years. Patients often present with highly malignant disease with limited treatment options. This highlights the need to understand the molecular mechanisms driving disease progression to better understand how to treat these patients. One particular gene imbalance that is highly prevalent in pancreatic cancer is in KRAS, a GTPase that is mutated in more than 90% of pancreatic cancer cases. When genome instability occurs, it creates an imbalance that increases the mutant:wildtype ratio of this gene. Recent work from our laboratory has shown that pancreatic cancer with a copy number imbalance in mutant KRAS are more aggressive and chemoresistant compared to cases where KRAS is balanced (equal number of mutated and wild type). <strong>I hypothesize that KRAS imbalances lead to upregulation of genes that mediate a survival/growth and contribute to therapy resistance. </strong>This project seeks to identify genes and pathways that are affected by mutant KRAS imbalance, to uncover molecular vulnerabilities that can eventually be targeted or combined with current chemotherapy. To do this I will generate a target genes using bulk RNA-seq from our recent paper (Chan et al., Nature Genetics, accepted) and use CRISPR to knockout these genes in a pancreatic cancer-derived 3D culture system (organoids). By understanding why these tumours are resistant to the current standards of care it is hoped that new therapeutic approaches can be discovered to improve patient prognosis. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Woo, Tristan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~